BCAX · Bicara Therapeutics Inc. · Executive Compensation
$17.26
+0.84 (+5.12%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$1.09B
Shares
66.17M
Volume · Oct 8
1.25M
Avg daily vol (3M)
620.37K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Claire Mazumdar | Chief Executive Officer | $927,688 |
| Ryan Cohlhepp | Pharm.D. President and Chief Operating Officer | $858,400 |
| David Raben | Chief Medical Officer The amounts reported represent the aggregate grant date fair value of stock option awards granted to our named executive officers during the applicable fiscal years, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. A discussion of the assumptions used in determining grant date fair value may be found in Note 10 to our financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon exercise of the applicable award or sale of the underlying shares of stock. The amounts reported for the fiscal year ended December 31, 2025 represent the annual bonuses each named executive officer earned under our annual cash bonus program based on achievement of company performance and individual performance during the applicable fiscal year, which were paid in the first quarter of fiscal year following the applicable fiscal year. The amounts reported represent employer profit sharing contributions and employer matching contributions earned by our named executive officers under our 401(k) plan during the applicable fiscal years. Dr. Raben was not a named executive officer for the fiscal year ended December 31, 2024. | $709,164 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Claire Mazumdar | Ph.D. M.B.A. Chief Executive Officer | $8,918,523 |
| Ryan Cohlhepp | Pharm.D. President and Chief Operating Officer | $4,467,589 |
| Ivan Hyep | M.B.A Chief Financial Officer | $3,598,836 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Claire Mazumdar | Ph.D. M.B.A. Chief Executive Officer | $4,543,323 |
| Ryan Cohlhepp | Pharm.D. President and Chief Operating Officer | $3,158,786 |
| Ivan Hyep | M.B.A Chief Financial Officer | $2,480,743 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kate Haviland | member of the Launch Readiness Committee of the Board | Appointed | 2026-07-28 |
| Carolyn Ng, Ph.D. | member of the Nominating and Corporate Governance Committee | Appointed | 2026-07-28 |
| Jeremy Bender, Ph.D. | member of the Audit Committee of the Board | Appointed | 2026-07-28 |
| Christy Oliger | member of the Nominating and Corporate Governance Committee | Appointed | 2026-07-28 |
| Jeremy Bender, Ph.D. | Class I director | Appointed | 2026-07-28 |
| Christy Oliger | Class II director | Appointed | 2026-07-28 |
| Kiran Mazumdar-Shaw | member of the Board of Directors | Resigned | 2026-07-28 |